Your session is about to expire
← Back to Search
Peer Navigation + Kidney Transplant Fast Track for Improving Access to Kidney Transplants in Minority Populations (AKT-MP Trial)
AKT-MP Trial Summary
This trial will compare two approaches to help Hispanic/Latino and American Indian patients overcome barriers to completing transplant evaluation and receiving a kidney transplant.
AKT-MP Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAKT-MP Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.AKT-MP Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am under 18 years old.I have had a kidney transplant.I am 18 years old or older.I currently have an infection that affects my whole body.I am mentally capable of making my own decisions.You are waiting to receive an organ transplant at a different hospital.I have not had cancer other than skin cancer in the past 2 years.I have been diagnosed with cognitive impairment.
- Group 1: Arm 1
- Group 2: Arm 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this clinical experiment currently recruiting volunteers?
"Clinicaltrials.gov is reporting that this clinical trial, which was originally launched on the 11th of January 2022 and last modified on the 24th of same month, presently has open enrollment for eligible patients."
What is the target enrollment for this clinical experiment?
"Affirmative, clinicaltrials.gov displays that this research is actively seeking participants. This trial was initially uploaded on 11th January 2022 and edited most recently on 24th January 2022. 398 subjects must be enrolled from one medical site for the study to continue."
Share this study with friends
Copy Link
Messenger